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In a provocative article published in this issue, Fedson and
Rordam argue that statins and angiotensin II receptor blockers
(ARBs) could be used as therapeutic agents in Ebola virus disease
(EVD). The authors assert that the loss of vascular integrity
represents a critical step in the pathophysiology of EVD, leading to
hypovolemia and multi-organ failure. Since every blood vessel in
the body is lined by endothelial cells and since, according to the
authors, statins and ARBs work to maintain or enhance endothelial
barrier integrity, these drugs might keep the patient alive long
enough for the immune system to clear the virus. Essentially, this
strategy seeks to modulate the host response to the infection
rather than combating the virus itself. The authors point out that
the loss of vascular integrity that is characteristic of human EVD is
not reproduced in most animal models. Because of this, the authors
note that the notion of targeting endothelial activation or leak in
EVD has not been widely accepted. In this editorial we will address
the biological plausibility of this approach and then address the
clinical evidence of its efﬁcacy.
2. Biological plausibility
The premise that the endothelium is critical to the pathogenesis
of severe infections is not new. In animal models of bacterial sepsis,
endothelial cell activation and increased endothelial permeability
contribute to mortality.1,2 Similar ﬁndings have been reported in
certain viral infections.3 For instance, activation of the endotheli-
um is critical to the pathogenesis of inﬂuenza,4 and we and others
have reported on the importance of lung endothelial barrier
integrity in murine models of inﬂuenza virus- induced acute lung
injury.2,5,6
Diarrhea and poor oral intake are major contributors to the
hypovolemia that characterizes human cases of EVD;7,8 however,
the loss of endothelial barrier integrity may also contribute. While
viral infection of the endothelium itself could conceivably cause
endothelial leak, in vitro experiments,9 as well as necropsy studies
on cynomolgus monkeys10 and autopsy studies on human
patients,11 suggest that this occurs only late in the disease.
However, monocytes are an early target of the Ebola virus,12 and
the massive activation of these cells and macrophages results in
the secretion of pro-inﬂammatory cytokines13,14 that can increase
endothelial permeability. In addition, secreted Ebola virus
glycoproteins have both direct and paracrine effects, including
inducing endothelial cell activation, loss of cellular adhesion, and
direct cytotoxicity.15–18 Finally, a recent study in mice reportedhttp://dx.doi.org/10.1016/j.ijid.2015.05.016
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).that genes associated with endothelial signaling and vascular
leakage correlated with resistance to a mouse-adapted strain of
Ebola.19 Together, these observations suggest an important and
perhaps unappreciated role for the endothelium in the pathogen-
esis of EVD.
3. Evidence of efﬁcacy
In their article, Fedson and Rordam present data from a case
series of approximately 100 consecutive patients in Sierra Leone
treated for six or more days with a combination of atorvastatin
40 mg and irbesartan 150 mg daily. Remarkably, the authors report
that ‘‘(o)nly two. . . died’’. While intriguing, these observations
must be interpreted cautiously. Importantly, no information is
provided as to the oversight and consent processes and no control
data are available—a particular shortcoming given that EVD
mortality varies signiﬁcantly in different clinical contexts.20,21
The authors provide very little detail about these patients, making
a critical appraisal of the results difﬁcult. Other published case
series emphasize the importance of adequate ﬂuid and electrolyte
replacement,8 and it is unclear whether statins and/or ARBs would
confer additional beneﬁt in the setting of optimal supportive care.
Furthermore, we are unsure whether statins and ARBs can
actually improve endothelial leak or activation in vivo. Statins have
been suggested to have pleiotropic anti-inﬂammatory effects
(reviewed by Tousoulis et al.22), including the ability to modulate
endothelial activation in sepsis,23 and observational trials initially
suggested that statin therapy had a protective effect in this context
(see meta-analysis by Wan et al.24). Unfortunately, randomized
controlled trials do not support this hypothesis. Indeed, in the trial
cited by Fedson and Rordam in which statin-naı¨ve septic patients
were treated with atorvastatin, there was no difference in the
length of hospital stay or the mortality rate between treatment and
control groups.25 Other larger trials have shown that statins do not
alter mortality26 from sepsis or the acute respiratory distress
syndrome.27 Several meta-analyses now suggest that statins do
not have clinically signiﬁcant effects on the outcome of severe
infection.24,28,29
The literature on ARBs as modulators of endothelial permeabil-
ity is not as complete. Angiotensin II has potent effects on the
vascular endothelium (reviewed by Salgado et al.30); for instance,
in rat tissue, angiotensin II modulates vascular leak,31 while mice
deﬁcient in Angiotensin Converting Enzyme, the enzyme that
generates angiotensin II, exhibit reduced susceptibility to acute
lung injury.32 Consistent with these ﬁndings, ARBs have been
shown to have lung-protective effects in a murine model ofciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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trials in humans with sepsis or lung injury. Human genetic studies
suggest that a polymorphism that would be expected to attenuate
angiotensin II signaling is actually associated with lower blood
pressure and increased mortality from sepsis.34 From a practical
standpoint, ARBs could be dangerous in severe infections, as
inhibition of angiotensin II signaling could contribute to renal
insult35 and hemodynamic instability.30
Ultimately, the efﬁcacy of statins and ARBs for EVD cannot be
properly evaluated without a formal, well-designed clinical trial.
Nonetheless, modulation of the endothelial response to Ebola
infection is a potentially promising approach that merits further
investigation. Finally, the development of better animal models for
Ebola-mediated vascular leak could be an important next step
towards the development of future therapeutics.
Acknowledgements
Research in WLL’s laboratory is supported by the Canadian
Institutes of Health Research (MOP130564).
Conﬂict of interest:.
References
1. Goldenberg NM, Steinberg BE, Slutsky AS, Lee WL. Broken barriers: a new take
on sepsis pathogenesis. Sci Transl Med 2011;3:88ps25.
2. London NR, Zhu W, Bozza FA, Smith MC, Greif DM, Sorensen LK, et al. Targeting
Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and
inﬂuenza. Sci Transl Med 2010;2:23ra19.
3. Steinberg B, Goldenberg N, Lee W. Do viral infections mimic bacterial sepsis?
The role of microvascular permeability: a review of mechanisms and methods.
Antiviral Res 2012;93:2–15.
4. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, et al. Endothe-
lial cells are central orchestrators of cytokine ampliﬁcation during inﬂuenza
virus infection. Cell 2011;146:980–91.
5. Armstrong SM, Wang C, Tigdi J, Si X, Dumpit C, Charles S, et al. Inﬂuenza infects
lung microvascular endothelium leading to microvascular leak: role of apopto-
sis and claudin-5. PLoS One 2012;7:e47323.
6. Wang C, Armstrong SM, Sugiyama MG, Tabuchi A, Krauszman A, Kuebler WM,
et al. Inﬂuenza primes human lung microvascular endothelium to leak upon
exposure to Staphylococcus aureus. Am J Respir Cell Mol Biol 2015 Feb 18 [Epub
ahead of print].
7. Johnson DW, Sullivan JN, Piquette CA, Hewlett AL, Bailey KL, Smith PW, et al.
Lessons learned: critical care management of patients with Ebola in the United
States. Crit Care Med 2015;43:1157–64.
8. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al. Clinical
illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med
2014;371:2092–100.
9. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, et al. Patho-
genesis of Ebola hemorrhagic fever in primate models: evidence that hemor-
rhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J
Pathol 2003;163:2371–82.
10. Ikegami T, Miranda ME, Calaor AB, Manalo DL, Miranda NJ, Niikura M, et al.
Histopathology of natural Ebola virus subtype Reston infection in cynomolgus
macaques during the Philippine outbreak in 1996. Exp Anim 2002;51:447–55.
11. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism,
pathology and pathogenesis of Ebola and Marburg viruses. J Pathol
2015;235:153–74.
12. Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in
the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol
2005;37:1560–6.
13. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I,
et al. Inﬂammatory responses in Ebola virus-infected patients. Clin Exp Immunol
2002;128:163–8.
14. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal Zaire Ebola
virus infection is associated with an aberrant innate immunity and with
massive lymphocyte apoptosis. PLoS Negl Trop Dis 2010;4(10):e837.
15. Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A, et al. Distinct cellular
interactions of secreted and transmembrane Ebola virus glycoproteins. Science
1998;279:1034–7.16. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identiﬁcation of
the Ebola virus glycoprotein as the main viral determinant of vascular cell
cytotoxicity and injury. Nat Med 2000;6:886–9.
17. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P. Ebola virus glyco-
proteins induce global surface protein down-modulation and loss of cell
adherence. J Virol 2002;76:2518–28.
18. Escudero-Perez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE, Shed GP.
of Ebola virus triggers immune activation and increased vascular permeability.
PLoS Pathog 2014;10:e1004509.
19. Rasmussen AL, Okumura A, Ferris MT, Green R, Feldmann F, Kelly SM, et al. Host
genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance.
Science 2014;346:987–91.
20. Cenciarelli O, Pietropaoli S, Malizia A, Carestia M, D’Amico F, Sassolini A, et al.
Ebola virus disease 2013–2014 outbreak in West Africa: an analysis of the
epidemic spread and response. Int J Microbiol 2015;2015:769121.
21. Spencer C. Having and ﬁghting Ebola—public health lessons from a clinician
turned patient. N Engl J Med 2015;372:1089–91.
22. Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C.
Innate and adaptive inﬂammation as a therapeutic target in vascular disease:
the emerging role of statins. J Am Coll Cardiol 2014;63:2491–502.
23. Kouroumichakis I, Papanas N, Proikaki S, Zarogoulidis P, Maltezos E. Statins in
prevention and treatment of severe sepsis and septic shock. Eur J Intern Med
2011;22:125–33.
24. Wan YD, Sun TW, Kan QC, Guan FX, Zhang SG. Effect of statin therapy on
mortality from infection and sepsis: a meta-analysis of randomized and ob-
servational studies. Crit Care 2014;18:R71.
25. Patel JM, Snaith C, Thickett DR, Linhartova L, Melody T, Hawkey P, et al. Random-
ized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reduc-
ing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care 2012;16:R231.
26. Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, et al. A
multicenter randomized trial of atorvastatin therapy in intensive care patients
with severe sepsis. Am J Respir Crit Care Med 2013;187:743–50.
27. McAuley DF, Laffey JG, O’Kane CM, Perkins GD, Mullan B, Trinder TJ, et al.
Simvastatin in the acute respiratory distress syndrome. N Engl J Med
2014;371:1695–703.
28. Thomas G, Hraiech S, Loundou A, Truwit J, Kruger P, McAuley DF, et al. Statin
therapy in critically-ill patients with severe sepsis: a review and meta-analysis of
randomized clinical trials. Minerva Anestesiol 2015 Feb 18 [Epub ahead of print].
29. Deshpande A, Pasupuleti V, Rothberg MB. Statin therapy and mortality from
sepsis: a meta-analysis of randomized trials. Am J Med 2015;128. 410–7.e1.
30. Salgado DR, Rocco JR, Silva E, Vincent JL. Modulation of the renin–angiotensin–
aldosterone system in sepsis: a new therapeutic approach? Expert Opin Ther
Targets 2010;14:11–20.
31. Newton CR, Curran B, Victorino GP. Angiotensin II type 1 receptor activation
increases microvascular permeability via a calcium dependent process. J Surg
Res 2005;123:33–9.
32. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting
enzyme 2 protects from severe acute lung failure. Nature 2005;436:112–6.
33. Shen L, Mo H, Cai L, Kong T, Zheng W, Ye J, et al. Losartan prevents sepsis-
induced acute lung injury and decreases activation of nuclear factor kB and
mitogen-activated protein kinases. Shock 2009;31:500–6.
34. Nakada TA, Russell JA, Boyd JH, McLaughlin L, Nakada E, Thair SA, et al.
Association of angiotensin II type 1 receptor-associated protein gene polymor-
phism with increased mortality in septic shock. Crit Care Med 2011;39:1641–8.
35. Plataki M, Kashani K, Cabello-Garza J, Maldonado F, Kashyap R, Kor DJ, et al.
Predictors of acute kidney injury in septic shock patients: an observational
cohort study. Clin J Am Soc Nephrol 2011;6:1744–51.
Niall C. Filewoda
Warren L. Leea,b,*
aInterdepartmental Division of Critical Care,
University of Toronto, Toronto, Ontario, Canada
bKeenan Research Centre, St. Michael’s Hospital,
Toronto, Ontario, Canada
E-mail address: warren.lee@utoronto.ca (W.L. Lee).
Received 11 May 2015
Accepted 13 May 2015
